CEPI Expands COVID-19 Vaccine Portfolio, But Pleads For Big Funding Boost
Six Programs Now Under Way
As the coronavirus continues its global spread, the global CEPI partnership is broadening its investment in programs that it hope will result in the rapid development and licensing of new vaccines.
You may also be interested in...
Phase III trial could lead to mid-2020 BLA filing to prevent seasonal influenza in adults 65 and older. Novavax also talked up the potential value of its adjuvant in COVID-19 vaccine development.
Recent collaborations involving Ridgeback, Themis, Junshi, Moleculin, Can-Fite, Pluristem and Beroni highlight the intense increase in research in how to treat or prevent COVID-19.
With the coronavirus outbreak gathering pace around the world, the UK is taking steps to assess companies’ ability to deal with potential medicine supply shortages, and has made additional funding available for vaccine and diagnostic research. Yet more funding to help the UK tackle the outbreak has just been announced in the 11 March budget.